Research Analysts Issue Forecasts for ZVRA FY2024 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities researchers at HC Wainwright dropped their FY2024 earnings estimates for shares of Zevra Therapeutics in a note issued to investors on Wednesday, November 20th. HC Wainwright analyst O. Livnat now expects that the company will post earnings per share of ($1.92) for the year, down from their previous forecast of ($1.74). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.96) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.36) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at $0.77 EPS and FY2027 earnings at $1.86 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter last year, the business posted ($0.40) earnings per share.

A number of other research analysts also recently weighed in on ZVRA. Maxim Group raised their target price on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. JMP Securities initiated coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 target price on the stock. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Canaccord Genuity Group lowered their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Price Performance

ZVRA stock opened at $9.59 on Friday. The stock has a 50-day moving average price of $8.19 and a two-hundred day moving average price of $6.63. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.64. The stock has a market cap of $511.61 million, a PE ratio of -4.87 and a beta of 1.93. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84.

Institutional Trading of Zevra Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. International Assets Investment Management LLC increased its holdings in shares of Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after acquiring an additional 5,940 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in Zevra Therapeutics during the first quarter worth $64,000. The Manufacturers Life Insurance Company increased its holdings in shares of Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after purchasing an additional 2,452 shares during the last quarter. Hunter Associates Investment Management LLC acquired a new stake in shares of Zevra Therapeutics during the 3rd quarter worth about $92,000. Finally, XTX Topco Ltd bought a new stake in shares of Zevra Therapeutics during the 3rd quarter worth about $94,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.